SAN DIEGO --(BUSINESS WIRE)--May 5, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021 .
SAN DIEGO --(BUSINESS WIRE)--Aug. 9, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021 .
SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15,
Foundation offers COVID-19 testing and support to more than 2.1 million students as part of campus health services SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation
Company to also co-host roundtable discussion SAN DIEGO , April 6, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testing SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to
Clinical utility and clinical validation of CTCs and ctDNA to analyze cancer biomarkers ALK, ROS1 and EGFR demonstrated SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of
Target Selector™ platform demonstrates ability to accurately detect, enumerate, and interrogate circulating tumor cells (CTCs) in a cohort of over 1,500 patients, representing various clinical and treatment stages of breast cancer SAN DIEGO , Dec. 3, 2019 /PRNewswire/ -- Biocept, Inc .
Clinical Data Shows Assay's Utility in Therapeutic Management of Patients with Non-Small Cell Lung Cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer,